Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Ana I. Stancic has been named Senior Vice President and Chief Financial Officer of the Company, effective June 8, 2011. Ms. Stancic has more than 20 years of extensive and diversified finance, accounting and operational experience in the health care industry. In her new position, Ms. Stancic will oversee Enzon’s financial planning, strategy and controls as well as its investor relations and information technology functions, reporting to Ralph del Campo, Chief Operating Officer and Principal Executive Officer of Enzon. Mark Ogden, who has served as Acting Vice President, Finance and Principal Financial Officer while the Company conducted a search for a Chief Financial Officer, will remain as a consultant to Enzon on accounting and financial matters during a transition period.